Zacks Investment Research • Jan 26, 2026
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
The Motley Fool • Jan 26, 2026
Abbott's stock plunged after the company reported lower-than-expected Q4 revenue last week. However, Abbott's revenue growth should accelerate in 2026.
Defense World • Jan 26, 2026
DiaSorin (OTCMKTS:DSRLF - Get Free Report) and Abbott Laboratories (NYSE: ABT - Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based o...
Seeking Alpha • Jan 25, 2026
Dividend Kings underperformed SPY in 2025, averaging 4.91% total return versus SPY's 17.72%, though 14 Kings outperformed the index. 2026 began strongly for Dividend Kings, up 4.66% through January 23...
Benzinga • Jan 25, 2026
Last week's biggest large-cap decliners included AeroVironment, DraftKings, AppLovin and Abbott, pressured by news, earnings and analyst actions.
Seeking Alpha • Jan 25, 2026
Abbott Laboratories is rated 'Buy,' following a recent price drop, driven by Nutrition segment weakness and COVID-19 diagnostics decline. ABT's Medical Devices segment, especially CGM, continues to de...
Defense World • Jan 25, 2026
Commerzbank Aktiengesellschaft FI lifted its stake in shares of Abbott Laboratories (NYSE: ABT) by 9.3% in the third quarter, according to its most recent filing with the SEC. The fund owned 245,168 s...
Defense World • Jan 25, 2026
Cullen Frost Bankers Inc. raised its holdings in Abbott Laboratories (NYSE: ABT) by 3.5% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutiona...
MarketBeat • Jan 24, 2026
Abbott Laboratories' NYSE: ABT January 2026 price pullback is making its stock look attractively valued. The move, driven more by market angst and fear than by any real weaknesses, seems to be a knee-...
Seeking Alpha • Jan 24, 2026
Abbott Laboratories experienced a post-earnings sell-off driven by weakness in its Nutrition segment and a sizable revenue miss. Despite segment headwinds, ABT delivered double-digit bottom-line growt...
Defense World • Jan 24, 2026
Abbott Laboratories (NYSE: ABT - Get Free Report) has been given an average recommendation of "Moderate Buy" by the twenty-two analysts that are covering the stock, Marketbeat reports. Three equities ...
Zacks Investment Research • Jan 23, 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Forbes • Jan 23, 2026
Abbott Laboratories reported Q4 2025 sales of $11.46 billion, an increase of 4.4% from the previous year but falling short of analyst projections by approximately 3%. The adjusted EPS was $1.50, align...
Seeking Alpha • Jan 23, 2026
Last month, Abbott Laboratories hiked its dividend for the 54th consecutive year. The company's FreeStyle Libre and Volt PFA System franchises, as well as its pending acquisition of Exact Sciences, po...
Reuters • Jan 23, 2026
Indian drugmaker Abbott Healthcare's supply chain is being scrutinised as part of a wider investigation into the alleged misuse of its codeine-based cough syrup which is prone to abuse by addicts, doc...
GuruFocus • Jan 22, 2026
Release Date: January 22, 2026For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Abbott Labora
WSJ • Jan 22, 2026
The medical-products maker's shares tumbled after its quarterly profit and sales underwhelmed investors.
Seeking Alpha • Jan 22, 2026
Abbott Laboratories (ABT) Q4 2025 Earnings Call Transcript
Zacks Investment Research • Jan 22, 2026
Jobless Claims Come in Slightly Higher.
Benzinga • Jan 22, 2026
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 200 points on Thursday.